


PHARMACEUTICAL 2022

Aerovate Therapeutics Inc. Rank 59 of 475





PHARMACEUTICAL 2022



Aerovate Therapeutics Inc. Rank 59 of 475

The relative strengths and weaknesses of Aerovate Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aerovate Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 214% points. The greatest weakness of Aerovate Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 108%, being 384% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	174,333
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,550
Liabilities, Non-Current	382
Other Assets	844
Other Compr. Net Income	-59
Other Expenses	3.0
Other Liabilities	13
Other Net Income	62
Property and Equipment	186
Research and Development	14,987
Revenues	0
Selling, General and Administrative Expense	8,035

Output Variable	Value in 1000 USD
Assets	175,363
Liabilities	2,945
Expenses	23,025
Stockholders Equity	172,418
Net Income	-22,963
Comprehensive Net Income	-22,992
Economic Capital Ratio	108%